Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China

BACKGROUND AND OBJECTIVE: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, especially in China. According to the 2021 Chinese Society of Clinical Oncology guidelines, sorafenib, lenvatinib, atezolizumab combined with bevacizumab, and sintilimab combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Hongyu, Ong, Siew Chin, Li, Fan, Weng, Zhiying, Zhao, Keying, Jiang, Zhengyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064722/
https://www.ncbi.nlm.nih.gov/pubmed/37004046
http://dx.doi.org/10.1186/s12962-023-00435-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064722/
https://www.ncbi.nlm.nih.gov/pubmed/37004046
http://dx.doi.org/10.1186/s12962-023-00435-x

Ejemplares similares